Medicare Benefits Schedule - Item 73295

Search Results for Item 73295

View Associated Notes

Category 6 - PATHOLOGY SERVICES

73295

73295 - Additional Information

Item Start Date:
01-Feb-2017
Description Updated:
01-Aug-2020
Schedule Fee Updated:
01-Feb-2017

Group
P7 - Genetics

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with advanced (FIGO III-IV) high-grade serous or high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible, requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme (PBS)

Maximum of one test per patient’s lifetime

Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,112.10

(See para PN.0.27 of explanatory notes to this Category)


Associated Notes

Category 6 - PATHOLOGY SERVICES

PN.0.27

Germline BRCA gene mutation tests (Items 73295, 73296 and 73333)

Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.

Related Items: 73295 73296 73333


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change